IRIvania Rizo

Ivania Rizo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ivania Rizo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Aya Bassatne

    Section of Endocrinology Diabetes and Nutrition, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine , Boston, MA 02118

    2 shared publications
  • Kathryn L. Fantasia

    Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

    2 shared publications
  • Alejandro Campos

    Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine Mayo Clinic Rochester Minnesota USA

    1 shared publication
  • Caroline M. Apovian

    Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States

    1 shared publication
  • Christopher Lee

    Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

    1 shared publication
  • Colin Pierce

    1 shared publication

Latest Publications

  • Medical treatments for obesity: what does the future have in store?

    by Aya Bassatne, Ivania Rizo

    Context: Obesity is a chronic relapsing disease associated with substantial morbidity, mortality, and health care costs. Contemporary obesity pharmacotherapies extend beyond weight reduction, with evidence for improvements across multiple obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care. Evidence Acquisition: A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026. Reference lists of relevant reviews were screened to identify additional eligible studies. Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included. Evidence Synthesis: Entero-pancreatic hormone-based therapies targeting glucagon-Like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, amylin, and glucagon pathways demonstrate substantial efficacy beyond weight reduction. These hormones act through complementary mechanisms regulating appetite, energy balance, and metabolic homeostasis. GLP-1 based agents achieve approximately 10-15% weight loss, whereas agents targeting multiple pathways demonstrate greater efficacy. Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20% and the triple agonist retatrutide produced reductions exceeding 25%. Beyond weight loss, these agents improve glycemia, support diabetes prevention, and produce organ-specific benefits, including reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, improvement of metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and reduced osteoarthritis-related pain. Conclusion: Next-generation obesity pharmacotherapies represent a major advance in obesity management and support a treat-to-target approach prioritizing improvement in obesity-related complications and metabolic health. Effective implementation will require individualized therapy and attention to long-term safety, access, and equitable delivery of care.


  • Open Access

    Future Directions in the Medical Treatment of Obesity: A Narrative Review

    by Aya Bassatne, Ivania Rizo

    Obesity remains a major global health challenge with increasing prevalence rates despite decades of long-standing efforts focused on lifestyle interventions, pharmacotherapy, and surgery. The rapid development of highly effective incretin-based therapies has transformed obesity care by achieving clinically significant and substantial weight loss. Building on this success, an expanding therapeutic pipeline—including dual and triple agonists, amylin analogues, and other multimodal agents—targets complementary pathways and more closely aligns treatment with the biological complexity of obesity. Together, these advancements offer a promising future for long-term, sustainable obesity management and may help shift population-level trends. This review summarizes current evidence from published trials on the mechanisms, efficacy, and safety of approved and investigational medications, and highlights the potential impact of these therapies on the evolving landscape of obesity care.

  • Ectopic Cushing Syndrome Secondary to Metastatic Small Cell Carcinoma of Unknown Primary: A Multidisciplinary Approach

    by Colin Pierce, Niyoti Reddy, Joseph Rencic, Umit Tapan, Ivania M. Rizo, Rizo Im

    Home Page right<div style="disp

  • Diabetes After Bariatric Surgery

    by Jenny C. Bello-Ramos, Ivania M. Rizo, Sara M. Alexanian

  • Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital

    by Kathryn L Fantasia, Kamonkiat Wirunsawanya, Christopher Lee, Ivania Rizo

    Limited data exist regarding diabetes technology use among adults with type 1 diabetes (T1D) in urban racially/ethnically diverse safety-net hospitals. We examined racial/ethnic differences in the use of continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) in this setting. A retrospective review of 227 patients ≥ 18 years of age with T1D seen in an urban, safety-net endocrinology clinic during 2016-2017 was completed (mean age: 39; 80% English-speaking; 50% had public insurance). Diabetes technology use, defined as either CGM or CSII or both CGM and CSII, and clinical outcomes were examined by race/ethnicity. Overall, 30% used CGM and 26% used CSII. After adjusting for age, language, insurance, and annual income, diabetes technology use in non-White patients was significantly lower than in White patients, predominantly lower in Black (aOR 0.25 [95% CI 0.11-0.56]) and patients identified as other race/ethnicity (aOR 0.30 [95% CI 0.11-0.77]). At the highest household income level (≥$75,000/y), Black and Hispanic individuals were significantly less likely than White individuals to use diabetes technology (P < .0007). Mean hemoglobin A1c (HbA1c) was lower in patients using any diabetes technology compared with patients using no technology (P < .0001). Use of CGM and CSII together was associated with the lowest HbA1c across all racial/ethnic groups. Racial/ethnic disparities in diabetes technology use and glycemic control were observed even after adjusting for sociodemographic factors. Further research should explore barriers to accessing diabetes technology in non-White populations.


  • Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity

    by Eric Nolen-Doerr, Mary-Catherine Stockman, Ivania Rizo

    The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).


  • Open Access

    Diabetic Ketoacidosis Post Bariatric Surgery

    by Ivania M. Rizo, Caroline M. Apovian

    In patients with type 2 diabetes, bariatric surgery can lead to significant improvements in glycemic control and diabetes remission. We present a case of a Hispanic female with type 2 diabetes phenotype who underwent bariatric surgery and post-operatively stopped her insulin therapy due to multiple reasons, including decreased oral intake and concern for hypoglycemia. Ultimately, she developed diabetic ketoacidosis. She does not fit into the classical type 2 diabetes or type 1 diabetes definition but into the heterogeneous subgroup of diabetes called ketosis-prone diabetes.